Literature DB >> 23931274

Viral RNA polymerase: a promising antiviral target for influenza A virus.

Fangyuan Shi1, Yuanchao Xie, Lifang Shi, Wenfang Xu.   

Abstract

Influenza A virus, which has a high rate of morbidity and mortality, has become a serious threat to human health and society. Because of antigenic variation, the application of influenza vaccination is limited. Till now, the current antivirals are mainly against the M2 protein (such as adamantanes) and the neuraminidase (such as zanamivir and oseltamivir). However, many viral strains have developed resistance to these marketed antiviral drugs, and it is urgent to find new antivirals for the prevention and treatment of influenza. RNA polymerase that is crucial for the replication and transcription in the virus life cycle has been proved to be an effective target for design of new antivirals. In this review, we describe the recent progress of the structure, function, and inhibitors of the novel target.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23931274     DOI: 10.2174/09298673113209990208

Source DB:  PubMed          Journal:  Curr Med Chem        ISSN: 0929-8673            Impact factor:   4.530


  10 in total

1.  The PA Endonuclease Inhibitor RO-7 Protects Mice from Lethal Challenge with Influenza A or B Viruses.

Authors:  Jeremy C Jones; Bindumadhav M Marathe; Peter Vogel; Rodolfo Gasser; Isabel Najera; Elena A Govorkova
Journal:  Antimicrob Agents Chemother       Date:  2017-04-24       Impact factor: 5.191

Review 2.  Influenza A Virus Nucleoprotein: A Highly Conserved Multi-Functional Viral Protein as a Hot Antiviral Drug Target.

Authors:  Yanmei Hu; Hannah Sneyd; Raphael Dekant; Jun Wang
Journal:  Curr Top Med Chem       Date:  2017       Impact factor: 3.295

3.  Targeting Influenza A Virus RNA Promoter.

Authors:  Angel Bottini; Surya K De; Bainan Wu; Changyan Tang; Gabriele Varani; Maurizio Pellecchia
Journal:  Chem Biol Drug Des       Date:  2015-03-13       Impact factor: 2.817

4.  A Novel Endonuclease Inhibitor Exhibits Broad-Spectrum Anti-Influenza Virus Activity In Vitro.

Authors:  Jeremy C Jones; Bindumadhav M Marathe; Christian Lerner; Lukas Kreis; Rodolfo Gasser; Philippe Noriel Q Pascua; Isabel Najera; Elena A Govorkova
Journal:  Antimicrob Agents Chemother       Date:  2016-08-22       Impact factor: 5.191

Review 5.  Compounds with anti-influenza activity: present and future of strategies for the optimal treatment and management of influenza. Part I: Influenza life-cycle and currently available drugs.

Authors:  R Gasparini; D Amicizia; P L Lai; N L Bragazzi; D Panatto
Journal:  J Prev Med Hyg       Date:  2014-09

Review 6.  Influenza virus polymerase inhibitors in clinical development.

Authors:  Frederick G Hayden; Nahoko Shindo
Journal:  Curr Opin Infect Dis       Date:  2019-04       Impact factor: 4.915

7.  Structural Basis of SARS-CoV-2 Polymerase Inhibition by Favipiravir.

Authors:  Qi Peng; Ruchao Peng; Bin Yuan; Min Wang; Jingru Zhao; Lifeng Fu; Jianxun Qi; Yi Shi
Journal:  Innovation (N Y)       Date:  2021-01-18

8.  Structural and Thermodynamic Analysis of the Resistance Development to Pimodivir (VX-787), the Clinical Inhibitor of Cap Binding to PB2 Subunit of Influenza A Polymerase.

Authors:  Jiří Gregor; Kateřina Radilová; Jiří Brynda; Jindřich Fanfrlík; Jan Konvalinka; Milan Kožíšek
Journal:  Molecules       Date:  2021-02-14       Impact factor: 4.411

9.  Structural and Biochemical Characterization of the nsp12-nsp7-nsp8 Core Polymerase Complex from SARS-CoV-2.

Authors:  Qi Peng; Ruchao Peng; Bin Yuan; Jingru Zhao; Min Wang; Xixi Wang; Qian Wang; Yan Sun; Zheng Fan; Jianxun Qi; George F Gao; Yi Shi
Journal:  Cell Rep       Date:  2020-05-30       Impact factor: 9.423

Review 10.  An Overview of the Crystallized Structures of the SARS-CoV-2.

Authors:  Mihaela Ileana Ionescu
Journal:  Protein J       Date:  2020-10-24       Impact factor: 4.000

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.